ACAAI 2018

Because of the prevalence of behavioral health issues in elderly patients with asthma, appropriate behavioral health treatment may improve patient outcomes.

Upadacitinib, a selective janus kinase-1 inhibitor, was associated with early improvements in pruritus in patients with moderate to severe atopic dermatitis.

More than 67% of patients who received AR101 were able to ingest a dose of 600 mg or more of peanut protein at the exit food challenge, without dose-limiting symptoms

Significant improvements were seen in lung function in patients who received either dose of beclomethasone dipropionate.

Patients who received reslizumab experienced significantly greater improvements in each sleep-related related Asthma Quality of Life Questionnaire question score compared with placebo.

Patients with both asthma and allergies had a significant increase in the number of prescriptions dispensed for controller medications.

GSP301 treatment was associated with a significant improvement in reflective and instantaneous Total Nasal Symptom Scores compared with placebo.

The mean proportion of days covered in the fluticasone furoate/vilanterol group was significantly higher than in the budesonide/formoterol and fluticasone propionate/salmeterol groups.

By day 3, patients with severe eosinophilic asthma who received benralizumab required less use of rescue medication.

Significantly greater reductions in the mean esophageal eosinophil counts occurred in patients who received the humanized anti-interleukin 13 antibody, RPC4046.